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Many thanks to you all – farewell until we meet again
Hannes Wahlroos
Professor, Director General (until 12.2.2009)
National Agency for Medicines
Editorial
This is my last Editorial for the TABU journal, so
please allow me to reminisce a little.
The inception of the journal can be dated back to
spring 1991. The Medicines Department of the
Board of Social Affairs and Health, which was es-
tablished on the vestiges of the National Board of
Health, wanted to launch a journal targeted at cus-
tomers and stakeholder groups, with an emphasis on
medicines regulation and other issues related to the
pharmaceutical industry. The first publication of
TABU’s leaflet, Tiedote 1/1992, consisted of eight
folded photocopied pages. The Editor responsible
for the leaflet was Pekka Eränkö, an experienced
writer. TABU, in its present format as a journal, was
launched at the beginning of 1993 and I became the
Editor at that point.
The leaflet, Tiedote 1/1992, contained a paper by
me on its first page, discussing the aims of the publi-
cation, TABU. I would particularly like to quote the
following paragraph:
“Pharmaceutical administration is being reorgan-
ised once again. A working group of the Ministry
of Social Affairs and Health will make a proposal
by the end of January 1992 for the establishment
of a pharmaceutical agency under the leadership 
of the Ministry. Essentially, this would lead to the 
amalgamation of the Board of Social Affairs and 
Health and the Medicines Laboratory. Irrespec-
tive of the rearrangement of the pharmaceutical 
administration as a single organisation, the medi-
cines regulatory authorities will without doubt 
need TABU or an equivalent channel of informa-
tion of their own.”
This was very much to the point, and is what
eventually happened. Hopefully, pharmaceutical ad-
ministration will have its own voice in future, too.
At its best, as several reader surveys through the
years have shown, TABU’s relevance to its readership
is evident. A good publication and good communica-
tion also reinforce the identity and profile of the or-
ganisation.   
Apart from that obtained through reader surveys,
feedback about TABU has been very limited. I can,
nevertheless, think of two examples: Soon after the
launch, one reader, a medical doctor, repeatedly re-
quested his name to be removed from the distribu-
tion list because TABU, as the name of a journal, in
his mind, was insulting, anathema and degrading.
He did receive a few more issues before the dispatch-
es were successfully cancelled. Another example was
a reader, a pharmacist, who sent me a postcard de-
picting beautiful flowers accompanied with encour-
aging text to congratulate me on my editorial article.
It lifted my spirits for many days from then on.
Even the name of the journal has generated re-
sponses. A glance at the top shelves of magazine dis-
plays in shops reveals that another journal called
TABU is published in Finland, but in the field of
adult entertainment. Despite the risk of confusion,
NAM has steadfastly held on to the name of its
journal. Between the editors, there were never dis-
putes about the right to use the name.
The pharmaceutical sector relies on TABU and
the papers published in it have a faithful readership.
For this I am grateful to the many colleagues I have
at NAM. I also extend my gratitude to the external
collaborators and authors who, from their viewpoint
of practical pharmaceutical care and the pharmaceu-
tical sector, have ensured the trustworthiness of the
papers. The greatest recognition for the production
of the journal is nevertheless due to Inari Stenberg,
Pirkko Paakkari, Erkki Palva and Marja Forsell,
who have formed the core editorial team throughout
the years and worked to bring TABU to the fore to
become an important pharmaceutical publication in
Finland.
On the threshold of changes, I would like to wish
all readers of TABU plenty of good reading in the fu-
ture – in one way or another. Thank you all for your
cooperation!
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Heikki Valleala
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Helsinki University Central Hospital
Yrjö Konttinen
M.D., Ph.D.
Professor of Internal Medicine
Helsinki University Central Hospital
According to an extensive study
carried out in the UK, a long-
term, low-dose cortisone therapy
(prednisone 2.5–7.5 mg/day) is
associated with a 2.6-fold  (95 %
CI 2.2–3.3) increased risk of ver-
tebral fracture. With a daily dose
of prednisone higher than 7.5 mg
the risk of vertebral fracture was
increased 5.2-fold (95 % CI 4.3–
6.3) in patients in whom the most
common therapeutic indication
for glucocorticoids was respirato-
ry disease (1). The risk of frac-
tures increased significantly as
early as within three months of
the introduction of the cortisone
therapy. However, in little more
than a year after discontinuing
the therapy the risk of fractures
decreased to the level of that of
the control subjects. 
In another study, extraverte-
bral fractures were found to in-
crease by 54% during the first
year of therapy with a dose of
prednisone of over 7.5 mg per
day. The risk of fractures corre-
lated more closely with (each)
daily dose than with the cumula-
tive total dose (2). In patients on
glucocorticoid treatment, bone
fractures occur at higher bone
density values in comparison
with those who do not receive
this treatment (2). The explana-
tion is thought to be the reduced
bone quality due to the effect of
glucocorticoid therapy. 
The pathogenesis of GOP
Following the introduction of
glucocorticoid therapy the bone
mineral density is rapidly reduced
due to increased bone resorption.
As the glucocorticoid therapy is
continued, the rate of bone loss
slows down and is mainly due to
reduced bone formation. Gluco-
corticoid therapy mainly effects
the rapidly forming cancellous
bone rather than the more slowly
renewable cortical bone. Indirect
effects include reduced absorp-
tion of calcium from the intesti-
nal tract and reduced reabsorp-
tion in the kidneys. Glucocorti-
coids also reduce the secretion of
gonadotro-pins and the growth
hormone, which results in in-
creased bone catabolism and re-
duced regeneration. The catabolic
effect of glucocorticoid therapy
on the musculature also causes
myasthenia, which can increase
the risk of falls (3).
The direct effect of glucocorti-
coids on the bone cells is an im-
portant factor in the pathogenesis
of  GOP. According to data ob-
tained from animal studies, glu-
cocorticoids increase the effect of
bone-catabolising osteoclasts by
prolonging the lifetime of these
cells (4). This explains the rapid
reduction in bone density after
the introduction of glucocorticoid
therapy. Nevertheless, glucocorti-
coids increase the programmed
cell death rate of osteoblasts and
osteocytes thereby reducing their
activity (5). Oseoblasts are cells
on the outer surface of bone
which form new bone; their ac-
tivity is reduced by glucocorti-
coids. Bone-forming osteoblasts
are imbedded in the bone and de-
velop into osteocytes, located in
lacunae in the mineralised bone
matrix, forming a three-dimen-
sional cell network amongst
themselves, as well as linking
with other bone cells. Osteocytes
play an important role as sensors
of mechanical loading of the
bone and promote the repair of
micro-damages accumulated in
the bone. If osteocytic function is
inhibited, the result may be an
accumulation of irreversible mi-
crodamages, which reduces the
bone’s biomechanical quality.
Glucocorticoids therefore also in-
crease the risk of fractures by
mechanisms which are indepen-
dent of changes in the bone den-
sity (5, 6).
In the prevention and treat-
ment of GOP, an important con-
sideration is that bisphospho-
nates, as well as oestrogens and
calcitonin, protect osteocytes
against cell death caused by glu-
cocorticoids (6). This effect has
been found in bisphosphonates
even at rather low concentra-
tions, and the various bisphos-
phonates are equally effective in
this respect. The antiresorptive
efficacy varies greatly between
Glucocorticoid therapy is the most important cause of secondary osteoporosis and a common 
indication for medical prophylaxis against osteoporosis.
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the different bisphosphonates,
with the most recent aminobis-
phosphonates being over a thou-
sand times more potent in com-
parison with the first generation
bisphosphonate, etidronate (7).
The medical treatment of GOP
It should be ensured that every-
one on steroid therapy has an ad-
equate daily intake of calcium
and vitamin D. Bisphosphonate
or other effective anti-osteoporo-
sis medication is often also need-
ed to prevent glucocorticoid-in-
duced osteoporosis (8, 9). Wal-
lach et al. (10) reported that a
daily dose of 5 mg risedronate
had, within one year, reduced the
relative risk of new vertebral
fractures by 70% in comparison
with a placebo. The average lum-
bar vertebral T-score at the start
of the study was -1.2 and the av-
erage dose of prednisone used
throughout the study was 12 mg
per day. At the end of the study
the difference between the groups
regarding the change in bone
density in the lumbar vertebrae
was less than 3 %. The rather
small difference in the bone den-
sities between the groups cannot
explain the significant decrease in
the number of vertebral fractures
in the active treatment group.
The decrease in the risk of frac-
tures was based, in all probabili-
ty, on the ability of bisphospho-
nates to inhibit the negative ef-
fect that glucocorticoid therapy
has on bone qualitative proper-
ties.
In a recent study, 18 months
treatment with teriparatide in-
creased the lumbar vertebral
bone density significantly more
than a daily dose of alendronate
(7.2% vs. 3.4%). More impor-
tantly, a significantly smaller
number of new vertebral frac-
tures were detected in the teri-
paratide group (0.6% vs. 6%)
(11). The result supports the per-
ception that teriparatide is escpe-
cially appropriate in the treat-
ment of severe axial osteoporo-
sis. 
Future perspectives
In addition to the parathormone
analogue teriparatide, other bone
therapies with an anabolic effect
may also be beneficial in the
treatment and prevention of
GOP. The effect of glucocorti-
coids on osteoblasts is mediated
partly via the inhibition of the
important Wnt signalling path in
the osteoblastogenesis. By in-
hibiting Wnt antagonists, the ef-
fect of glucocorticoids on the os-
teoblasts could be reversed; one
example is the monoclonal anti-
body against sclerostin (AMG
785) (3, 12). For example, stron-
tium ranelate, one of the current
anti-osteoporosis drugs, increases
bone formation and inhibits its
catabolism and would, in theory,
be very appropriate in the treat-
ment of GOP. 
Another approach is the at-
tempt to develop new glucocorti-
coids with anti-inflammatory ef-
fect but less effect on bone.
These types of drugs include ni-
trosteroids, the effect of which is
enhanced by their slow release of
NO; glucocorticoids which accu-
mulate in inflamed tissues and
are incorporated into liposomes;
and, in particular, the selective
glucocorticoid receptor agonists
(SEGRA), which have a dissocia-
tive effect, i.e. anti-inflammatory
effect via transrepression, but no
adverse effects transmitted via
transactivation (13). Budesonide
exerts an anti-inflammatory ef-
fect in the bowel, but, due to the
effective first-pass metabolism,
concentrations in the systemic
circulation remain low.
Treatment recommendations
for GOP
An adequate daily intake of calci-
um (a minimum of 1 000 mg)
and vitamin D (800 IU) is recom-
mended for everybody on steroid
therapy (14). Bisphosphonates
are the drug group of choice for
the prevention and treatment of
GOP. The American College of
Rheumatology (ACR) recom-
mends bisphosphonates for pa-
tients who are prescribed pred-
nisone therapy (5 mg/day or
higher) for a period of three
months at least. Those who have
used prednisone (5 mg/day) for
longer, are advised to commence
bisphosphonate therapy with os-
teopenic bone density values (T-
score < -1) (15). According to a
Dutch recommendation (Figure,
see p. 5), bisphosphonate should
be prescribed when prednisone is
started at a dose > 15 mg/day.
When the daily dose of pred-
nisone is 7.5–15 mg/day, the in-
troduction of bisphosphonate
therapy is recommended in post-
menopausal women and in men
over 70 years old. A decision to
start anti-osteoporosis therapy in
patients younger than this is
based on the result of bone den-
sity measurement and general
risk factor assessment (16). It is
recommended that the risk as-
sessment should cover all the fac-
tors which increase the risk of
fracture, independent of bone
density. There is a new interna-
tional fracture assessment tool
(FRAX) to use for this assess-
ment (17;www.shef.ac.uk/
FRAX/) and a similar Finnish os-
teoporosis index (18, 19). In the
prevention of fractures it is also
important to identify and elimi-
nate other risk factors for falls
(by optimising CVS and CNS
medication, improving vision and
lighting, improving safety in the
home and environment, using
walking aids, making the correct
choice of shoes, and using anti-
slip devices) (20). Hip protectors
used by nursing home patients
have been proven to decrease hip
fractures, but their use is associ-
ated with various problems such
as compliance (21, 22). 
Literature
See page 6.
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A review of the activities of pharmaceutical
wholesalers
According to Section 77 of the
Medicines Act (395/1987), it is
the responsibility of the National
Agency for Medicines to inspect
pharmaceutical establishments as
often as required by the appro-
priate pharmaceutical regulation.
In practice, in addition to the in-
spections, regulation is carried
out by means of standardized
guidance, general advice given to
entrepreneurs and by various re-
views.
NAM’s Administrative Regu-
lation regarding good distribu-
tion practices for pharmaceutical
wholesalers was revised during
2007, and the new Regulation
4/2007 came into force on
1.1.2008. In January 2008 NAM
sent 92 drug wholesalers a re-
quest for a review of the compa-
ny’s pharmaceutical wholesale
activities. In the review question-
naire the licensees were asked for
details about their accountable
director, about their drug distrib-
ution and its scale, storage of
drugs, product defects, customer
complaints, and about obligatory
storage arrangements. Besides the
reviews, companies were also
asked to submit to NAM copies
of standard operating procedures
relating to returned products and
customer complaints, and regard-
ing procedures on shelf life and
transport temperatures.
The replies received showed
that some of the licensees had
neither started their licensed ac-
tivity at all, or the business had
been suspended for longer than
the license allowed. Consequent-
ly, in addition to the cancellation
of some licenses, the review also
resulted in a great number of re-
newals of wholesale licences. In
2008, NAM processed a total of
63 applications from pharmaceu-
tical wholesalers. The number of
applications from pharmaceutical
wholesalers increased by about
62% in total in comparison with
2007 (n=39), (fig.).
The review questionnaire
served its purpose well in reflect-
ing the present situation relating
to pharmaceutical wholesalers at
an opportune moment, with the
new Administrative Regulation
regarding their licensed activity
coming into force. The review
will facilitate improved, more
precise targeting of enforcement
activities on pharmaceutical
wholesalers, keeping in mind fu-
ture challenges. The review clear-
ly also improved the maintenance
of pharmaceutical wholesalers’
own quality system.
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Figure. Total number of decisions concerning licenses of pharmaceutical
wholesalers in 2008.
Cancellation of licensesNew licenses Alteration of licenses
n=51
n=5 n=7
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